Evolus Ownership
| EOLS Stock | USD 9.20 0.14 1.50% |
Shares in Circulation | First Issued 2016-03-31 | Previous Quarter 63.4 M | Current Value 63.7 M | Avarage Shares Outstanding 39.3 M | Quarterly Volatility 17.5 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evolus Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. Evolus Stock Ownership Analysis
About 85.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.89. Evolus Inc had not issued any dividends in recent years. Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. The company was incorporated in 2012 and is headquartered in Newport Beach, California. Evolus operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 174 people. To learn more about Evolus Inc call David Moatazedi at 949 284 4555 or check out https://www.evolus.com.Evolus Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Evolus is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Evolus Inc backward and forwards among themselves. Evolus' institutional investor refers to the entity that pools money to purchase Evolus' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Stonepine Capital Management Llc | 2025-03-31 | 1.1 M | Soleus Capital Management, L.p. | 2025-03-31 | 1.1 M | Schroder Investment Management Group | 2025-03-31 | 1 M | Nuveen, Llc | 2025-03-31 | 1 M | Soros Fund Management Llc | 2025-03-31 | 995.5 K | Ubs Group Ag | 2025-03-31 | 953.7 K | Great Point Partners Llc | 2025-03-31 | 944.7 K | Rice Hall James & Associates, Llc | 2025-03-31 | 921.4 K | D. E. Shaw & Co Lp | 2025-03-31 | 877.1 K | Tang Capital Management Llc | 2025-03-31 | 5 M | Blackrock Inc | 2025-03-31 | 4.3 M |
Evolus Inc Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Evolus insiders, such as employees or executives, is commonly permitted as long as it does not rely on Evolus' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Evolus insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Evolus Outstanding Bonds
Evolus issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Evolus Inc uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Evolus bonds can be classified according to their maturity, which is the date when Evolus Inc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Evolus Corporate Filings
F4 | 16th of June 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 6th of June 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 15th of May 2025 Other Reports | ViewVerify | |
| 25th of April 2025 Other Reports | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Evolus Stock Analysis
When running Evolus' price analysis, check to measure Evolus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evolus is operating at the current time. Most of Evolus' value examination focuses on studying past and present price action to predict the probability of Evolus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evolus' price. Additionally, you may evaluate how the addition of Evolus to your portfolios can decrease your overall portfolio volatility.